Formulation and Development of Iguratimod Film Coated Tablets 25 mg

Authors

  • Rekha Kandukuri
  • Mekkanti Manasa Rekha
  • Rinku Mathappan
  • C. Pavithra
  • R. Aruna

DOI:

https://doi.org/10.37591/tdd.v7i1.714

Abstract

Iguratamide is chemically called as methanesulfonanilid for the treatment of rheumatoid arthritis. The present invention relates to the micron zing technology for insoluble polycrystal medicine Iguratimod, and the micronized Iguratimod has new crystallization and powder direct compression method for formulating tablets. The orally taken quick release preparation with micronized Iguratimod as active component, high efficiency super disintegrants like cross carmellose sodium, surfactants like sodium lauryl sulphate, diluents like MCC PH 102, Lactose DC GRADE etc. have obviously improved in vitro leaching rate and in vivo absorption rate, and obviously raised bioavailability.

 

Keywords: Iguratimod, Lactose DC Grade, Mannitol DC Grade, sodium lauryl sulphate, cross carmellose sodium, hydroxy propyl cellulose, Povidone K-30 and Opadry white

 

Cite this Article

Rekha Kandukuri, Mekkanti Manasa Rekha, Rinku Mathappan, C. Pavithra, R. Aruna. Formulation and Development of Iguratimod Film Coated Tablets 25 mg. Trends in Drug Delivery. 2020; 7(1): 25–31p.

Downloads

Published

2020-05-12

Issue

Vol. 7 No. 1 (2020)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.